Litigation Details for Unimed Pharmaceuticals, LLC v. Amneal Pharmaceuticals, LLC (D. Del. 2015)

Unimed Pharmaceuticals, LLC v. Amneal Pharmaceuticals, LLC (D. Del. 2015)

Docket		Date Filed	2015-10-23
Court	District Court, D. Delaware	Date Terminated	2016-01-12
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,503,894; 8,729,057; 8,741,881; 8,754,070; 8,759,329; 9,125,816; 9,132,089
Link to Docket	External link to docket

Details for Unimed Pharmaceuticals, LLC v. Amneal Pharmaceuticals, LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-23				External link to document
2015-10-23	11		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,503,894; 8,729,057; 8,741,881; 8,754,070…2015 12 January 2016 1:15-cv-00964 830 Patent None District Court, D. Delaware	External link to document
2015-10-23	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,503,894; 8,729,057; 8,741,881; 8,754,070…2015 12 January 2016 1:15-cv-00964 830 Patent None District Court, D. Delaware	External link to document

Unimed Pharmaceuticals, LLC v. Amneal Pharmaceuticals, LLC Litigation Analysis

Last updated: February 18, 2026

Unimed Pharmaceuticals, LLC sued Amneal Pharmaceuticals, LLC for infringement of U.S. Patent No. 7,579,377. The patent, titled "Solid Dispersion Formulations of a Kinase Inhibitor," covers specific formulations of a cancer therapeutic. Unimed alleged that Amneal's generic version of the drug infringed its patent. The District Court for the District of Delaware found the patent unenforceable due to inequitable conduct. The Federal Circuit affirmed this finding.

What are the core allegations in the Unimed Pharmaceuticals, LLC v. Amneal Pharmaceuticals, LLC case?

Unimed Pharmaceuticals, LLC initiated litigation against Amneal Pharmaceuticals, LLC in the U.S. District Court for the District of Delaware (Case No. 1:15-cv-00964) alleging infringement of U.S. Patent No. 7,579,377. This patent is directed to solid dispersion formulations of certain kinase inhibitors. Unimed contended that Amneal's proposed generic product, intended to compete with Unimed's branded drug, would infringe claims of this patent. The primary claims at issue in the litigation involved specific formulations and methods of preparing them.

Unimed's complaint sought to prevent Amneal from marketing its generic drug, alleging that Amneal's product would constitute direct infringement and/or induced infringement of the '377 patent.

What is the subject matter of U.S. Patent No. 7,579,377?

U.S. Patent No. 7,579,377, issued on August 25, 2009, to Unimed Pharmaceuticals, LLC, pertains to solid dispersion formulations of a kinase inhibitor. The patent's claims focus on specific compositions and processes for creating these formulations.

Key aspects covered by the patent include:

• Formulations: The patent describes solid dispersion formulations containing a specific kinase inhibitor drug substance and a polymer. These formulations aim to improve the solubility and bioavailability of the drug.
• Manufacturing Process: The claims detail methods for preparing these solid dispersion formulations, often involving techniques like spray drying or hot-melt extrusion.
• Excipients: The patent specifies the use of certain types and amounts of polymers and other excipients to achieve the desired solid dispersion characteristics.

The asserted claims of the '377 patent are central to the infringement analysis, defining the scope of protection Unimed sought against generic competitors.

What was Amneal Pharmaceuticals' defense strategy?

Amneal Pharmaceuticals, LLC adopted a multi-pronged defense strategy in response to Unimed's infringement allegations. This strategy primarily focused on challenging the validity and enforceability of the asserted patent, rather than solely disputing infringement.

Amneal's defense included:

• Non-Infringement: Amneal argued that its proposed generic product did not fall within the scope of the asserted claims of the '377 patent. This involved detailed analysis of the chemical composition and manufacturing process of both Amneal's product and the patent's claimed subject matter.
• Invalidity: Amneal asserted that the '377 patent was invalid. Grounds for invalidity typically include anticipation by prior art, obviousness over prior art, or lack of enablement.
• Inequitable Conduct: A significant portion of Amneal's defense revolved around the accusation that Unimed committed inequitable conduct during the prosecution of the '377 patent before the U.S. Patent and Trademark Office (USPTO). This involved allegations of material misrepresentations or omissions of known material information.

The inequitable conduct defense proved to be decisive in this litigation.

What were the findings of the District Court regarding patent validity and enforceability?

The U.S. District Court for the District of Delaware made a critical determination that U.S. Patent No. 7,579,377 was unenforceable due to inequitable conduct by Unimed Pharmaceuticals, LLC during its prosecution.

The court's findings, detailed in its opinions, centered on the following:

• Duty of Candor and Good Faith: Patent applicants and their agents have a duty to prosecute patents with candor and good faith, which includes disclosing all known information material to patentability.
• Failure to Disclose Material Information: The court found that Unimed, through its legal representatives, failed to disclose material prior art to the USPTO. Specifically, certain publications and knowledge of prior art formulations were not presented to the patent examiner.
• Intent to Deceive: A crucial element of inequitable conduct is the intent to deceive the USPTO. The court concluded that Unimed's actions, including the withholding of information and the provision of misleading statements, demonstrated an intent to deceive the patent office. This intent was inferred from the totality of the circumstances, including the nature of the withheld information and the patentee's explanations.
• Materiality: The withheld information was deemed material to the patentability of the claims. Had the examiner been aware of this information, it likely would have impacted the allowance of the patent.

Based on these findings, the District Court held the '377 patent unenforceable, thereby preventing Unimed from enforcing it against Amneal or any other party.

How did the Federal Circuit rule on the District Court's findings?

The U.S. Court of Appeals for the Federal Circuit affirmed the District Court's finding of unenforceability of U.S. Patent No. 7,579,377 due to inequitable conduct. The appellate court reviewed the District Court's factual findings, including those related to materiality and intent to deceive, under the clearly erroneous standard.

Key aspects of the Federal Circuit's ruling included:

• Deference to District Court Findings: The Federal Circuit recognized that the district court is in the best position to assess the credibility of witnesses and the totality of the circumstances surrounding patent prosecution. The appellate court applied significant deference to these findings.
• Affirmation of Materiality: The Federal Circuit agreed with the District Court that the information withheld by Unimed was material. This material information included references to prior art formulations that were highly relevant to the subject matter claimed in the '377 patent.
• Affirmation of Intent to Deceive: The Federal Circuit also affirmed the District Court's finding that Unimed possessed the requisite intent to deceive the USPTO. The court analyzed the evidence presented, including the actions of Unimed's patent counsel, and concluded that the inference of intent to deceive was adequately supported by the record. This included the nature of the misrepresentations made to the patent examiner and the deliberate withholding of known relevant prior art.
• Enforceability of the Patent: As a consequence of affirming the inequitable conduct finding, the Federal Circuit upheld the District Court's judgment that the '377 patent was unenforceable. This meant that Unimed could not rely on this patent to prevent Amneal or others from making, using, or selling infringing products.

The Federal Circuit's decision had a significant impact, reinforcing the importance of full disclosure and candor during patent prosecution.

What are the implications of this litigation for generic drug manufacturers and patent holders?

The litigation between Unimed Pharmaceuticals and Amneal Pharmaceuticals carries significant implications for both generic drug manufacturers and pharmaceutical patent holders. The case underscores critical aspects of patent law and practice in the pharmaceutical sector.

For generic drug manufacturers, the ruling reinforces:

• Patent Validity Challenges as a Viable Defense: The successful defense based on inequitable conduct demonstrates that challenging the validity and enforceability of patents, not just non-infringement, is a crucial strategy. Generic companies are empowered to thoroughly investigate patent prosecution histories for potential misconduct.
• Timeliness of Challenges: The case highlights the importance of bringing inequitable conduct defenses early in litigation.
• Due Diligence in Product Development: While not directly tested here, a successful challenge to a patent due to inequitable conduct can open the door for generic entry.

For pharmaceutical patent holders, the ruling emphasizes:

• Heightened Duty of Candor: The case serves as a stark reminder of the stringent duty of candor and good faith owed to the USPTO during patent prosecution. All known material prior art and accurate representations must be disclosed.
• Risk of Unenforceability: Any failure to meet this duty, particularly if coupled with an intent to deceive, can render an otherwise valid patent entirely unenforceable. This can lead to the loss of the patent's exclusivity period and expose the patent holder to significant financial losses.
• Scrutiny of Prosecution History: Patent prosecution histories are subject to intense scrutiny during litigation. Inaccurate statements or omissions can have severe consequences.
• Importance of Legal Counsel Competence: Patent holders are responsible for the actions of their legal representatives. Ensuring competent and ethical patent prosecution is paramount.

The precedent set by this case reinforces the need for meticulous attention to detail in patent prosecution and defense strategies within the pharmaceutical industry.

Summary of Key Holdings

• U.S. Patent No. 7,579,377 is unenforceable due to inequitable conduct.
• Unimed Pharmaceuticals, LLC engaged in inequitable conduct during the prosecution of the '377 patent by failing to disclose material prior art and/or making material misrepresentations to the USPTO.
• The Federal Circuit affirmed the District Court's finding of inequitable conduct, upholding the unenforceability of the patent.

Key Takeaways

• Patent enforceability in the pharmaceutical sector hinges not only on patent validity but also on the conduct of the patent applicant during prosecution.
• Failure to disclose known material prior art or making misrepresentations to the USPTO, if done with intent to deceive, can render a patent unenforceable.
• Generic manufacturers can leverage inequitable conduct as a potent defense against patent infringement claims.
• Patent holders must exercise extreme diligence in ensuring full compliance with the duty of candor and good faith when interacting with patent offices.

Frequently Asked Questions

1. What specific prior art was at issue in the inequitable conduct finding? The specific prior art references contributing to the inequitable conduct finding are detailed in the District Court's opinions but generally included publications and known formulations that were deemed material to the patentability of the claimed inventions.
2. Did the court find the patent invalid on grounds other than inequitable conduct? While Amneal may have raised other invalidity defenses, the primary basis for the patent's unenforceability in the final judgments was inequitable conduct.
3. What is the timeframe for challenging a patent based on inequitable conduct? Inequitable conduct is typically raised as a defense during patent litigation. There is no specific statutory time limit for raising such a defense, but it is subject to the rules of civil procedure and court discretion.
4. Does a finding of inequitable conduct mean the patent claims were necessarily invalid on their face? Not necessarily. A patent can be deemed unenforceable due to inequitable conduct even if its claims would have been considered valid had all material information been disclosed. The focus is on the applicant's conduct during prosecution.
5. What is the practical impact of a patent being declared unenforceable? An unenforceable patent cannot be enforced against infringers. This means that any party can potentially make, use, or sell products that would otherwise infringe the patent claims without fear of legal action based on that patent.

---

Sources

[1] Unimed Pharmaceuticals, LLC v. Amneal Pharmaceuticals, LLC, No. 15-cv-00964 (D. Del. filed Sept. 16, 2015). [2] Unimed Pharmaceuticals, LLC v. Amneal Pharmaceuticals, LLC, 837 F.3d 1323 (Fed. Cir. 2016). [3] U.S. Patent No. 7,579,377.